Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
The Lancet. Respiratory Medicine|December 19, 2017
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic studyChia-Chi Lin, Jin-Yuan Shih, Chong-Jen Yu, et al.Clinical and Translational Medicine|December 23, 2024
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysisShang-Gin Wu, Chao-Chi Ho, James Chih-Hsin Yang, et al.Oncology|October 1, 2023
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint InhibitorsDerek De-Rui Huang, Bin-Chi Liao, Wei-Hsun Hsu, et al.Journal of Cancer|May 29, 2018
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in TaiwanShu-Yung Lin, Ching-Yao Yang, Bin-Chi Liao, et al.The Oncologist|January 16, 2024
Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based TherapyHsing-Wu Chen, Yao-Wen Kuo, Chung-Yu Chen, et al.Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE studyGee-Chen Chang, Chien-Hua Tseng, Kuo-Hsuan Hsu, et al.European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.The Oncologist|May 10, 2020
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.Nature Nanotechnology|November 13, 2024
Layer-dependent evolution of electronic structures and correlations in rhombohedral multilayer grapheneYang Zhang, Yue-Ying Zhou, Shihao Zhang, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.Pageof 9